Amgen remains a defensive staple for investors, leveraging a strong dividend yield and diversified drug pipeline to navigate broader economic instability and market corrections.
Amgen has historically outperformed broader equities during market downturns and continues to grow revenue with a strong pipeline and dividend.
Novartis's Pelacarsen failure is cited as a negative read-through for Amgen's similar drug olpasiran.
Nvidia is referenced as a past top stock pick with massive returns, not central to the current article about Amgen.
Amgen demonstrates historical resilience during market downturns, notably outperforming the S&P 500 during the 2008 recession and the 2022 bear market. Driven by a robust portfolio of essential medicines and a consistent dividend growth strategy, the biotech firm maintains revenue growth despite patent cliffs and competitive pressures in its clinical pipeline.
Amgen shares fell following the failure of Novartis's Pelacarsen in a cardiovascular trial, which raised investor concerns regarding the efficacy of Amgen's similar drug candidate, olpasiran.